<p>The British government on Friday said it has asked its independent medicines regulator to study Pfizer/BioNTech's coronavirus vaccine with a view to an imminent roll-out.</p>.<p>The announcement came after the pharma giant and its German partner said they will ask US regulators for emergency use authorisation for the vaccine in what would be a major step towards fighting back against the global pandemic.</p>.<p>In another potential boost, a UK study indicated individuals infected with coronavirus are unlikely to catch the illness again for at least six months.</p>.<p>Health Secretary Matt Hancock said the government had formally asked the Medicines and Healthcare products Regulatory Agency to assess the Pfizer/BioNTech vaccine for its suitability.</p>.<p>If approval was given, the vaccine would be free "at the point of delivery" across the UK from the country's state-run National Health Service (NHS).</p>.<p>The service would be ready to start a mass vaccination programme next month if the MHRA gave its agreement on the jab, he told a news conference.</p>.<p>Britain -- one of the world's most-affected countries by the outbreak with more than 54,000 deaths from 1.4 million cases -- has ordered 40 million doses.</p>.<p>Researchers at the University of Oxford said its large-scale study into Covid-19 re-infection had produced promising results.</p>.<p>The study was launched after observations from healthcare professionals that re-infection was relatively rare.</p>.<p>"We can be confident that, at least in the short term, most people who get Covid-19 won't get it again," said Oxford University Professor David Eyre, one of the authors.</p>.<p>The authors highlighted they had not yet gathered enough data to make a judgement on re-infection after six months.</p>.<p>However, the ongoing study has an end goal of verifying how long protection lasts in total.</p>.<p>The director of infection prevention and control at study partners Oxford University Hospitals (OUH), Katie Jeffery, called the finding "exciting".</p>.<p>It indicated "that infection with the virus provides at least short-term protection from re-infection", she added.</p>.<p>US biotech firm Moderna announced this week its vaccine candidate was nearly 95 per cent effective in a trial -- a week after similar results were announced by Pfizer and BioNTech.</p>.<p>The World Health Organization (WHO) welcomed the Oxford study saying the findings extended its understanding of coronavirus protection.</p>.<p>"We really commend the researchers for doing those studies," WHO emergencies director Michael Ryan told reporters in Geneva, explaining the findings had delivered the "best data".</p>.<p>Ryan added the antibody response detailed in the research gave "hope for longer periods of protection" from vaccine candidates.</p>.<p>The Oxford study into re-infection drew on data from regular coronavirus testing of 12,180 health care workers at OUH over a period of 30 weeks.</p>.<p>It found that none of the 1,246 staff with coronavirus antibodies developed a symptomatic infection.</p>.<p>Three members of staff with antibodies did test positive for the virus that causes Covid-19 but were all well and did not develop symptoms.</p>.<p>The WHO said it is working with 50 countries where studies on antibody responses in different groups, such as in the general population or among healthcare workers, were taking place.</p>.<p>The UN health body said it was pooling those results to give a broader picture of how the pandemic was developing.</p>
<p>The British government on Friday said it has asked its independent medicines regulator to study Pfizer/BioNTech's coronavirus vaccine with a view to an imminent roll-out.</p>.<p>The announcement came after the pharma giant and its German partner said they will ask US regulators for emergency use authorisation for the vaccine in what would be a major step towards fighting back against the global pandemic.</p>.<p>In another potential boost, a UK study indicated individuals infected with coronavirus are unlikely to catch the illness again for at least six months.</p>.<p>Health Secretary Matt Hancock said the government had formally asked the Medicines and Healthcare products Regulatory Agency to assess the Pfizer/BioNTech vaccine for its suitability.</p>.<p>If approval was given, the vaccine would be free "at the point of delivery" across the UK from the country's state-run National Health Service (NHS).</p>.<p>The service would be ready to start a mass vaccination programme next month if the MHRA gave its agreement on the jab, he told a news conference.</p>.<p>Britain -- one of the world's most-affected countries by the outbreak with more than 54,000 deaths from 1.4 million cases -- has ordered 40 million doses.</p>.<p>Researchers at the University of Oxford said its large-scale study into Covid-19 re-infection had produced promising results.</p>.<p>The study was launched after observations from healthcare professionals that re-infection was relatively rare.</p>.<p>"We can be confident that, at least in the short term, most people who get Covid-19 won't get it again," said Oxford University Professor David Eyre, one of the authors.</p>.<p>The authors highlighted they had not yet gathered enough data to make a judgement on re-infection after six months.</p>.<p>However, the ongoing study has an end goal of verifying how long protection lasts in total.</p>.<p>The director of infection prevention and control at study partners Oxford University Hospitals (OUH), Katie Jeffery, called the finding "exciting".</p>.<p>It indicated "that infection with the virus provides at least short-term protection from re-infection", she added.</p>.<p>US biotech firm Moderna announced this week its vaccine candidate was nearly 95 per cent effective in a trial -- a week after similar results were announced by Pfizer and BioNTech.</p>.<p>The World Health Organization (WHO) welcomed the Oxford study saying the findings extended its understanding of coronavirus protection.</p>.<p>"We really commend the researchers for doing those studies," WHO emergencies director Michael Ryan told reporters in Geneva, explaining the findings had delivered the "best data".</p>.<p>Ryan added the antibody response detailed in the research gave "hope for longer periods of protection" from vaccine candidates.</p>.<p>The Oxford study into re-infection drew on data from regular coronavirus testing of 12,180 health care workers at OUH over a period of 30 weeks.</p>.<p>It found that none of the 1,246 staff with coronavirus antibodies developed a symptomatic infection.</p>.<p>Three members of staff with antibodies did test positive for the virus that causes Covid-19 but were all well and did not develop symptoms.</p>.<p>The WHO said it is working with 50 countries where studies on antibody responses in different groups, such as in the general population or among healthcare workers, were taking place.</p>.<p>The UN health body said it was pooling those results to give a broader picture of how the pandemic was developing.</p>